BAY 1214784

• Description :

  BAY 1214784 is a potent, selective, and orally active antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R) . BAY 1214784 is a spiroindoline derivative compound. BAY 1214784 effectively lowers plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability. BAY 1214784 has the potential for the research of uterine fibroids[1].

• UNSPSC :

  12352005

• Target :

  GnRH Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bay-1214784.html

• Purity :

  99.8

• Solubility :

  DMSO : 42 mg/mL (ultrasonic; warming)

• Smiles :

  O=S(N1[C@@](C2CC2)([H])C3(CCS(=O)(CC3)=O)C4=CC(C(NCC5=C(C=C(C=N5)C(F)(F)F)Cl)=O)=CC=C41)(C6=CC=C(C=C6)F)=O

• Molecular Formula :

  C29H26ClF4N3O5S2

• Molecular Weight :

  672.11

• References & Citations :

  [1]Panknin O, et al. Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women. J Med Chem. 2020;63 (20) :11854-11881

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1631164-25-4]